Regulator Of Cell Cycle (Rgcc) Expression During The Progression Of Alzheimer's Disease

Scott E. Counts

Elliott J. Mufson

Barrow Neurological Institute, elliott.mufson@dignityhealth.org

Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology

Recommended Citation
https://scholar.barrowneuro.org/neurobiology/342

This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been accepted for inclusion in Translational Neuroscience by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. For more information, please contact suefue.espe@commonspirit.org.
Regulator of Cell Cycle (RGCC) Expression During the Progression of Alzheimer’s Disease

Scott E. Counts*†‡ and Elliott J. Mufson§¶

*Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, USA
†Department of Family Medicine, Michigan State University, Grand Rapids, MI, USA
‡Hauenstein Neurosciences Center, Mercy Health Saint Mary’s Hospital, Grand Rapids, MI, USA
§Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA
¶Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA

Unscheduled cell cycle reentry of postmitotic neurons has been described in cases of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) and may form a basis for selective neuronal vulnerability during disease progression. In this regard, the multifunctional protein regulator of cell cycle (RGCC) has been implicated in driving G1/S and G2/M phase transitions through its interactions with cdc/cyclin-dependent kinase 1 (cdk1) and is induced by p53, which mediates apoptosis in neurons. We tested whether RGCC levels were dysregulated in frontal cortex samples obtained postmortem from subjects who died with a clinical diagnosis of no cognitive impairment (NCI), MCI, or AD. RGCC mRNA and protein levels were upregulated by ~50%–60% in MCI and AD compared to NCI, and RGCC protein levels were associated with poorer antemortem global cognitive performance in the subjects examined. To test whether RGCC might regulate neuronal cell cycle reentry and apoptosis, we differentiated neuronotypic PC12 cultures with nerve growth factor (NGF) followed by NGF withdrawal to induce abortive cell cycle activation and cell death. Experimental reduction of RGCC levels increased cell survival and reduced levels of the cdk1 target cyclin B1. RGCC may be a candidate cell cycle target for neuroprotection during the onset of AD.

Key words: Mild cognitive impairment (MCI); Alzheimer’s disease (AD); Cell cycle; Regulator of cell cycle (RGCC); Nerve growth factor (NGF); Apoptosis

INTRODUCTION

Several lines of evidence suggest that cell cycle reactivation occurs in postmitotic neurons in Alzheimer’s disease (AD) and its putative prodromal stage, mild cognitive impairment (MCI). The AD brain is characterized by neuronal expression of cell cycle regulatory proteins1–3 and DNA replication4–6, whereas we have demonstrated the presence of the cell cycle proteins proliferating cell nuclear antigen (PCNA), cyclin D1, and cyclin B1 in neurons in vulnerable brain regions in subjects with MCI7. Mechanistically, a link has been established between unscheduled cell cycle reentry and neuronal apoptosis, suggesting a pathogenic mechanism for neuronal selective vulnerability8–13. Moreover, the activation of several cell cycle-related kinases, including cdc2/cyclin-dependent kinase 1 (cdk1), cdc2-like kinase, cdk2, and cdk5, has been shown to phosphorylate tau and promote tau aggregation14–17. The mechanisms underlying aberrant neuronal cell cycle reentry during the onset of AD have not been firmly established, but various stressors such as DNA damage and neurotrophin dysregulation have been proposed18–22. Notably, the tumor suppressor protein p53, which induces cell cycle arrest and DNA repair in damaged proliferating cells, facilitates apoptosis when the neuronal milieu is presented with toxic insults23–25. Although the link between p53, cell cycle dysregulation, and apoptosis is unclear, p53 induces the expression of the multifunctional protein regulator of cell cycle (RGCC)26,27, which is highly expressed in many cancerous tissues28. RGCC has been shown to either induce S phase entry and mitosis or promote differentiation in nonneuronal cells, which appears to be context dependent25–32. Whether RGCC dysfunction might represent a novel pathway linking aberrant cell cycle activation and apoptosis in neurons during the progression of AD remains undetermined. In the

Received September 29, 2016; final acceptance January 9, 2017. Online prepub date: November 30, 2016. Address correspondence to Scott E. Counts, Ph.D., College of Human Medicine, Michigan State University, 333 Bostwick Avenue NE, Grand Rapids, MI 49503, USA. Tel: 616-234-0997; Fax: 616-234-0990; E-mail: scott.counts@hc.msu.edu

963-6897/17 $90.00 + .00
Printed in the USA. All rights reserved. DOI: https://doi.org/10.3727/096368916X694184
Copyright © 2017 Cognizant, LLC. E-ISSN 1555-3892 www.cognizantcommunication.com
present study, we measured RGCC mRNA and protein levels in frontal cortex samples obtained postmortem from individuals who died with an antemortem diagnosis of no cognitive impairment (NCI), MCI, or AD. We also tested whether RGCC expression impacted cell survival in an in vitro experimental paradigm for neuronal cell cycle-induced apoptosis.

MATERIALS AND METHODS

Subjects

Brain tissues from NCI (n=14), MCI (n=11), and mild/moderate AD (n=11) cases from both genders were obtained from participants in the Rush Religious Orders Study, a longitudinal clinical pathologic study of aging and AD in elderly Catholic clergy. Demographic, clinical, and neuropathological characteristics of the subjects are summarized in Table 1. Details of cognitive evaluations and diagnostic criteria have been extensively published. Briefly, a team of investigators performed annual neuropsychological performance testing including the Mini Mental State Exam (MMSE) and 17 additional neuropsychological tests referable to five cognitive domains: orientation, attention, memory, language, and perception. A Global Cognitive Score (GCS), consisting of a composite z-score calculated from this test battery, was determined for each participant. A board-certified neurologist with expertise in the evaluation of the elderly made the clinical diagnosis based on impairments in each of the five cognitive domains and a clinical examination. The diagnosis of dementia or AD met recommendations by the joint working group of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association. The distribution of the Braak stages of neurofibrillary tangles (NFT) and the National Institute on Aging and Reagan Institute (NIA-Reagan) criteria were determined for each case.

Table 1. Clinical, Demographic, and Neuropathological Characteristics by Diagnosis Category

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>NCI (n=14)</th>
<th>MCI (n=11)</th>
<th>AD (n=11)</th>
<th>p Value</th>
<th>Pairwise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) at death</td>
<td></td>
<td></td>
<td></td>
<td>0.1*</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>83.9 ± 4.5</td>
<td>84.4 ± 5.2</td>
<td>86.2 ± 5.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>76–92</td>
<td>72–91</td>
<td>78–95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (%) of males</td>
<td>6 (43%)</td>
<td>6 (54%)</td>
<td>6 (54%)</td>
<td>0.5†</td>
<td></td>
</tr>
<tr>
<td>Years of education</td>
<td></td>
<td></td>
<td></td>
<td>0.1*</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>19.1 ± 2.9</td>
<td>18.9 ± 4.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>15–22</td>
<td>8–24</td>
<td>14–21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (%) with ApoE ε4 allele</td>
<td>2 (14%)</td>
<td>2 (18%)</td>
<td>5 (45%)</td>
<td>0.01‡</td>
<td>AD &gt; NCI, MCI</td>
</tr>
<tr>
<td>MMSE</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001*</td>
<td>NCI, MCI &gt; AD</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>28.1 ± 0.9</td>
<td>26.8 ± 2.6</td>
<td>15.1 ± 7.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>26–29</td>
<td>22–30</td>
<td>0–27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global cognitive score</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001*</td>
<td>NCI, MCI &gt; AD</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>0.0 ± 0.3</td>
<td>−0.37 ± 0.4</td>
<td>−1.8 ± 0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>−0.5 to 0.4</td>
<td>−1.2 to 0.3</td>
<td>−2.8 to −0.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postmortem interval (h)</td>
<td></td>
<td></td>
<td></td>
<td>0.3*</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>4.7 ± 2.9</td>
<td>6.0 ± 3.3</td>
<td>5.4 ± 3.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>2.2–12.0</td>
<td>2.7–13.0</td>
<td>2.7–12.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution of Braak scores</td>
<td></td>
<td></td>
<td></td>
<td>0.1*</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I/II</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III/IV</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V/VI</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIA-Reagan diagnosis (likelihood of AD)</td>
<td></td>
<td></td>
<td></td>
<td>0.2*</td>
<td></td>
</tr>
<tr>
<td>No AD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>6</td>
<td>6</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CERAD diagnosis</td>
<td></td>
<td></td>
<td></td>
<td>0.2*</td>
<td></td>
</tr>
<tr>
<td>No AD</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Possible</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probable</td>
<td>6</td>
<td>3</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definite</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Kruskal–Wallis test, with Bonferroni correction for multiple comparisons.

†Fisher’s exact test, with Bonferroni correction for multiple comparisons.
Neurologic and Communicative Disorders and Stroke/AD and Related Disorders Association (NINCDS/ADRDA)\textsuperscript{37}. The MCI population was defined as subjects who exhibited impairment on neuropsychological testing but did not meet the criteria for AD or dementia. These criteria for MCI are consistent with those used by others in the field\textsuperscript{38}.

Tissue samples were accrued as previously reported\textsuperscript{34,39,40}. At autopsy, tissue from one hemisphere was immersion fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) in 0.1 M phosphate buffer (pH 7.2) for 24–72 h at 4°C. Tissue slabs from the opposite hemisphere were frozen at −80°C prior to collection of frontal cortex samples for quantitative polymerase chain reaction (qPCR) and biochemical analysis. A series of fixed tissue sections were prepared for neuropathological evaluation including visualization and quantitation of neocortical and hippocampal amyloid plaques and neurofibrillary tangles (NFTs) using antibodies directed against the Aβ peptide (Aβ; 4G8; Covance, Princeton, NJ, USA), tau (PHF1; a gift from Dr. Peter Davies)\textsuperscript{33,40}, as well as thioflavine-S (Sigma-Aldrich) histochemistry and a modified Bielschowsky silver stain (components from Fisher Scientific, Pittsburgh, PA, USA). Additional sections were stained for Lewy bodies using antibodies directed against ubiquitin and α-synuclein. Exclusion criteria included argyrophilic grain disease, frontotemporal dementia, Lewy body disease, mixed dementias, Parkinson’s disease, stroke, and hippocampal sclerosis. A board-certified neuropathologist blinded to the clinical diagnosis performed the neuropathological evaluation. Neuropathological criteria were based on National Institute on Aging (NIA)-Reagan, Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), and Braak staging\textsuperscript{41–43}. Amyloid burden and apolipoprotein E (ApoE) genotype were determined for each case as described previously\textsuperscript{33,40}.

qPCR

Total RNA from frozen frontal cortex (Brodmann area 10) samples was extracted using guanidine-isothiocyanate lysis (PureLink; Ambion, Waltham, MA, USA), and RNA integrity and concentration were verified using Bioanalysis (Agilent Technologies, Santa Clara, CA, USA). Samples were assayed on a real-time (RT)-PCR cycler (ABI 7500; Applied Biosystems, Foster City, CA, USA) in 96-well plates as described previously\textsuperscript{44–47}. qPCR was performed using TaqMan hydrolysis probe primer sets (Applied Biosystems) specific for amplification of the following human transcripts: rgcc (probe set Hs00204129_m1), tumor protein p53 (tp53; Hs01034249_m1), and cdk1 (Hs00938777_m1). A primer set specific for human glyceraldehyde 3-phosphate dehydrogenase (gapdh) (Hs02758991_g1) was used as a control housekeeping transcript. For PC12 cell culture experiments (see below), total RNA was extracted and assayed as described above using primers specific for rat cyclin b1 (ccnb1; probe set Rn01494180_g1; Applied Biosystems) and rat gapdh (Rn01775763_g1). The ΔΔ Ct (ddCT) method was employed to determine relative levels of each amplicon\textsuperscript{48–50}. Variance component analyses revealed relatively low levels of within-case variability, and the average value of the triplicate qPCR products from each case was used in subsequent analyses. Alterations in PCR product synthesis were analyzed by one-way analysis of variance (ANOVA) with Bonferroni correction for post hoc comparison. The level of statistical significance was set at α=0.05 (two sided).

Western Blotting

Frozen frontal cortex tissue samples from the same cases used for qPCR were sonicated in ice-cold homogenization buffer [20 mM Tris, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 1 mM ethylenediaminetetraacetic acid (EDTA), 10% sucrose, pH 7.4] containing protease inhibitors (2 mg/ml leupeptin, 0.01 U/ml aprotinin, 1 mg/ml pepstatin A, 1 mg/ml antipain, 2.5 mg/ml chymostatin, 10 mM benzamidine, 0.1 mM PMSF, 0.4 mg/ml TPCK, 0.4 mg/ml TLCK, 0.4 mg/ml soybean trypsin inhibitor, 0.1 mM sodium fluoride, and 0.1 mM sodium orthovanadate). All chemicals were purchased from Sigma-Aldrich. Samples were prepared by centrifugation at 100×g for 10 min at 4°C. The protein concentration of the resulting S1 supernatant was determined by the Bradford method (Bio-Rad, Hercules, CA, USA), which uses bovine serum albumin (BSA) as the protein standard. Sample proteins from the S1 fraction were denatured in sodium dodecyl sulfate (SDS; Fisher Scientific) loading buffer to a final concentration of 5 mg/ml. Proteins (25 µg/sample) were separated by SDS polyacrylamide gel electrophoresis (10%; Lonza, Basel, Switzerland), transferred to Immobilon-FL membranes (Millipore, Billerica, MA, USA), blocked in Tris-buffered saline (pH 7.4) containing 0.1% Tween 20 (Fisher Scientific) and 2% nonfat milk, and then incubated overnight at 4°C with rabbit polyclonal antiserum to RGCC (1:500; Novus Biologicals, Littleton, CO, USA). Blots were then incubated for 1 h with near-infrared-labeled goat anti-rabbit immunoglobulin G (IgG) secondary antiserum (IRDye 680LT; 1:10,000; Licor, Lincoln, NE, USA) and analyzed on an Odyssey imaging system (Licor). Following imaging, the membranes were stripped and reprobed with a mouse monoclonal β-actin antibody (1:20,000; Millipore) overnight followed by a 1-h incubation with near-infrared-labeled goat anti-mouse IgG secondary antiserum (IRDye 680LT; 1:10,000; Licor) and Odyssey imaging. Signals for RCGG were normalized to β-actin for quantitative analysis\textsuperscript{34,47,49}.
**PC12 Cell Culture**

PC12 cultures (a gift of Dr. Richard Burry, Ohio State University, Columbus, OH, USA) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% horse serum (Gibco, Grand Island, NY, USA), 5% FetalClone I bovine serum (HyClone, Logan, UT, USA), and 1% penicillin/streptomycin (Gibco). Cultures were plated at 10 K/cm² onto Matrigel-coated dishes (1%; Collaborative Biomedical; Becton Dickinson, Franklin Lakes, NJ, USA) in DMEM with 1.5% serum. PC12 cultures were grown for 1 week in the presence of 400 pm (~50 ng/ml) mouse 7S nerve growth factor (NGF; Alomone Labs, Jerusalem, Israel). Media were replaced on days 3 and 5 in vitro. On day 7, PC12 cells were rinsed and incubated with 50 nM RGCC or scrambled siRNA (Origene, Rockville, MD, USA)/1% Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA, USA) in OptiMEM (Gibco)/400 pm NGF for 18 h, then rinsed and exchanged into DMEM/1.5% serum without NGF for 48 h. Cultures were assayed for cell viability using the LIVE/DEAD assay (Thermo Fisher Scientific, Waltham, MA, USA). Sister cultures were analyzed for cyclin B1 (ccnb1) expression, as described above.

**Statistical Analysis**

Demographic variables (Table 1) were compared among clinical diagnostic groups by Kruskal–Wallis or Fisher’s exact tests with Bonferroni correction for pairwise comparisons. Transcript levels (qPCR), protein levels (Western blotting), and cell viability measures were compared among groups by one-way ANOVA with Bonferroni post hoc testing. The level of statistical significance was set at $p < 0.05$. RGCC protein levels across diagnostic groups were tested for associations with clinical and pathological variables using Spearman rank correlations. The level of statistical significance was set at $p < 0.01$.

**RESULTS**

**Subject Demographics**

The clinical diagnostic groups did not differ by age, gender, years of education, or postmortem interval (Table 1). There were significantly more subjects with an ApoE 4 allele in the AD (45%) group than in the NCI (14%) or MCI (18%) group. AD cases had significantly lower MMSE scores compared to both NCI and MCI ($p < 0.001$), whereas the latter two groups did not differ statistically (Table 1). GCS $z$-scores were significantly lower in the AD compared to the NCI and MCI cases ($p < 0.0001$). Subjects in the different clinical diagnostic groups displayed considerable overlap with respect to pathological diagnostic criteria. Pathological examination revealed that 64% of NCI, 64% of MCI, and 82% of AD cases were classified as Braak stages III–VI. Using

![Graph A](image1.png)

**Figure 1.** p53 (tp53) and protein regulator of cell cycle (rgcc) gene expression levels are increased in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Box plots show normalized mean (max/min) expression levels of (A) tp53, (B) rgcc, and (C) cdc/cyclin-dependent kinase 1 (cdk1) in no cognitive impairment (NCI), MCI, and AD cases. *$p < 0.05$ versus NCI, via one-way analysis of variance (ANOVA) with Bonferroni post hoc comparisons.
the NIA-Reagan criteria, 57% of NCI, 45% of MCI, and 55% of AD cases were classified as intermediate to high likelihood of AD (Table 1). For CERAD diagnosis, 57% of NCI, 45% of MCI, and 55% of AD cases received a diagnosis of probable/definite AD. Statistical analysis did not reveal any differences in pathology among the NCI, MCI, and AD groups.

**RCGG Expression Levels in MCI and AD**

qPCR analysis was performed to quantify RGGC (rgcc), p53 (tp53), and CDK1 (cdk1) gene expression levels in frozen frontal cortex tissue samples accrued from NCI, MCI, and AD subjects (Fig. 1). A significant ~55%–60% increase in rgcc transcript levels was measured in MCI compared to NCI cases (p<0.05), whereas rgcc levels were upregulated by ~50% in AD compared to NCI (p<0.05) (Fig. 1A). By contrast, tp53 expression levels were significantly increased by ~55%–60% in MCI and AD compared to NCI (p<0.05) (Fig. 1B), whereas there were no differences in cdk1 expression across the diagnostic groups (Fig. 1C).

To test whether RCGG protein levels were also upregulated in the MCI and AD cases, quantitative Western blotting was performed on tissue extracts from the same cases (Fig. 2). RGCC immunoreactivity (~15-kDa band) was higher in the MCI and AD frontal cortex compared to NCI (Fig. 2A). Quantitative analysis of the Western blots showed that normalized RGCC protein levels were significantly increased by ~50%–55% in MCI and AD (p<0.05). Spearman rank correlations showed no association between RGCC protein levels and age, gender, PMI, or ApoE status (data not shown). By contrast, increased RGCC protein levels were associated with poorer cognitive performance as measured by the MMSE (r=0.39, p=0.002) and GCS (r=0.43, p=0.005), but not with Braak, NIA-Reagan, or CERAD neuropathological criteria.

**Inhibition of RGCC Protects PC12 Cells From Nerve Growth Factor Withdrawal**

Neurontypic differentiation of rat PC12 cells with NGF, followed by NGF deprivation in low/no serum, results in aberrant cell cycle entry and apoptosis. In order to assess whether RGCC might play a role in neuronal apoptosis related to cell cycle reentry, we differentiated PC12 cells and then treated the cultures with rgcc-specific siRNA or scrambled control siRNA prior to NGF withdrawal (Fig. 3). There was an overall ~75% decrease in the cell survival of PC12 cultures subjected to NGF withdrawal compared to cultures maintained on NGF (p<0.01). By contrast, rgcc downregulation rescued the PC12 cultures from NGF deprivation, resulting in an ~25% decrease in cell survival compared to NGF-maintained cultures (Fig. 3A). To assess the extent of cell cycle activation in the cultures, we used qPCR to measure expression levels of cyclin b1 (ccnb1), a CDK1 binding partner that is downregulated during NGF-induced differentiation and upregulated during NGF withdrawal and apoptosis of PC12 cells. There was an overall ~80% increase in cyclin B1 levels in PC12 cultures subjected to NGF withdrawal compared to cultures maintained on NGF (p<0.05). By contrast, rgcc downregulation prevented cyclin B1 upregulation during NGF deprivation (Fig. 3B).

**DISCUSSION**

For over two decades, the concept of “abortive mitosis” has been noted as a cellular mechanism of apoptosis during development and neuronal cell death in neurodegenerative disease. With respect to AD, it has been proposed that deleterious events such as the loss of neurotrophic support needed to maintain terminal differentiation, or neuronal DNA damage from oxidative stress, result in the transition from a quiescent G0 cell cycle...
stage into an unscheduled attempt at DNA replication and mitosis. The consequent loss of genomic and cellular homeostasis ultimately triggers programmed cell death. Moreover, the activation of several cell cycle kinases, normally under tight regulatory control in postmitotic neurons, can lead to tau hyperphosphorylation and aggregation into NFTs. Hence, the cell cycle continues to represent a viable target for disease-modifying therapies for AD. Here we provide evidence that the cell cycle regulatory protein RGCC is upregulated in MCI and AD, correlates with global cognitive decline, and may be involved in facilitating aberrant cell cycle reentry induced by neurotrophin loss in differentiated neurons, suggesting that RGCC may be a candidate cell cycle target for neuroprotection during the onset of AD. This report may also add another provocative link to the potential mechanistic interrelationship between cell transformation in cancer and selective vulnerability in neurodegenerative disease. These diseases share many molecular pathogenic processes, including oxidative and inflammatory stress, proteostatic stress, and metabolic dysregulation, and it has been postulated that these pathways lead to either clonal expansion in proliferating cells or clonal elimination in terminally differentiated cells such as neurons.

The functional and mechanistic repertoire of RGCC activity has not been fully elucidated. It was originally discovered as the RGC-32 response gene during complement activation of rat oligodendrocytes. RGCC physically associates with and activates CDK1, a key kinase involved in the G1/S and G2/M phase transitions. However, RGCC has also been implicated in diverse functions such as cellular differentiation, inflammation, vascular remodeling, and insulin resistance. Interestingly, RGCC was identified as a transcriptional target and mediator of p53 tumor suppression in glioma cells. In neurons, the p53 protein possesses multifactorial properties regulating DNA damage, cell cycle control, and apoptosis. Given the evidence that p53 protein is upregulated and possibly dysregulated due to structural modifications in MCI and AD, we investigated whether RGCC was also upregulated in these disease stages and whether it could potentially play a role in neuronal cell cycle dysfunction and/or apoptosis. In this regard, we validated p53 upregulation but also found that RGCC was upregulated in the frontal cortex in MCI and AD. By contrast, transcripts encoding the RGCC-regulated cell cycle protein CDK1 were stable during disease progression despite a trend for upregulation, consistent with the notion that RGCC regulates CDK1 activity rather than expression.

The functional consequences of RGCC upregulation in MCI and AD subjects are unclear, but its role in cell cycle activation led us to test whether this upregulation...
and these mature peptides interact with their cognate
receptors derived from proNGF and proBDNF precursor proteins,
and NGF withdrawal-mediated cell cycle reactivation and apoptosis.
Using rggc and scrambled sequence control siRNA, we found that rggc knockdown protected
PC12 cells from NGF withdrawal and prevented the upregulation of the CDK1 binding partner cyclin B1,
suggesting that RCGG participates in cell cycle reactivation and cell death within the context of deficient neu-
rotrophin signaling.

A central concept underlying the selective vulnerabil-
ity of neurons in AD is that they are dependent on neu-
rotrophins such as NGF and brain-derived neurotrophic
factor (BDNF) for survival. NGF and BDNF are derived from proNGF and proBDNF precursor proteins, and these mature peptides interact with their cognate high-affinity receptors TrkA and TrkB, respectively, for prosurvival functions. By contrast, proNGF and proBDNF have higher affinity for the pan neurotrophin receptor p75NTR and elicit prodeath signals. Notably, we found that cortical TrkA protein levels were selectively reduced in mild AD compared to p75NTR, whereas cortical proNGF levels were elevated in MCI and AD compared to NCI. Hence, increased cortical proNGF in combination with reduced cortical TrkA expression may result in enhanced binding between proNGF and p75NTR, potentially shifting away from prosurvival NGF signaling to apoptotic signaling. Likewise, levels of BDNF and TrkB are decreased in vulnerable brain regions in MCI and AD. This observation, combined with the presence of cell cycle proteins within vulnerable brain regions in MCI and mild AD, suggests that neurotrophic receptor imbalance promotes a loss of neurotrophic support and unscheduled cell cycle reentry and apoptosis during the prodromal stages of AD. In this regard, whereas cell cycle abnormalities have been linked to in vitro and in vivo amyloid and tau pathology, we did not find a significant association between RGCC levels and neuropathological diagnostic criteria. This may be due to the lack of significant differences in Braak, NIA-Reagan, or CERAD scores among the diagnostic groups. On the other hand, they may suggest that neurotrophic imbalances affect RGCC and other cell cycle events independent of plaque or tangle burden. The extent to which increased RGCC levels denote its involvement in neurotrophin-mediated mitotic cell death cascades in the MCI and AD brain is a question for future study. Furthermore, given the involvement of p53 in neuronal apoptosis following NGF withdrawal, it will be interesting to explore whether a p53-RGCC-CDK1/cyclin B cascade mediates aberrant cell cycle activation in postmitotic neurons. If so, this pathway may present a novel therapeutic target for disease modification during the progression of AD.

ACKNOWLEDGMENTS: We are grateful for the altruism of the Religious Orders Study participants. This study was supported by the National Institutes of Health (NIH) grants PO1AG14449, RO1AG043375, R21AG026603, and R21AG042146; the Saint Mary’s Foundation; Miles for Memories of Battle Creek, MI; and Barrow Neurological Institute Barrow and Beyond. The authors declare no conflicts of interest.

REFERENCES
1. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle pro-
2. Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant expression of mitotic cd2/cyclin B1 kinase in degener-
11. Park DS, Levine B, Ferrari G, Greene LA. Cyclin depend-
ent kinase inhibitors and dominant negative cyclin depen-
13. Malik B, Currais A, Soriano S. Cell cycle-driven neu-


